Immunisation against the RS virus

We offer optional immunisation against respiratory syncytial virus (RSV). Beyfortus (Nirsevimab) is a ready-made monoclonal antibody which, once administered, provides immediate protection against RSV infection for several months. It is therefore not a conventional vaccination, which triggers a response from the child’s immune system, but rather ‘passive immunisation’ using a ready-made antibody.

A large proportion of children contract RSV; it is the most common cause of hospitalisation in children under one year of age. The disease often presents as lower respiratory tract inflammation affecting the small airways, leading to breathlessness and the need for oxygen therapy. The use of Beyfortus does not prevent a child from contracting this infection, but it significantly reduces the incidence of severe cases and the need for hospitalisation.

The product is administered by intramuscular injection; administration is not associated with systemic or local adverse reactions, as is often the case with routine vaccination.

Due to its limited duration of action, Beyfortus is administered only during the respiratory infection season, i.e. from October to March. Administration is recommended upon discharge from the maternity ward. For children born outside the respiratory infection season, administration is recommended at the start of the season, i.e. in October. This is arranged by the paediatrician.